Clinical predictors of survival in patients with castration-resistant prostate treated with sipuleucel-T cellular immunotherapy.
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 22 Jul 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.